Fully Automated PCR System for COVID-19 Detection

Expand COVID-19 PCR testing infrastructure to support mass testing.

The scientific community continues to call for large-scale and frequent testing as a key response to help manage the spread of COVID-19. Incorporating this strategy into COVID-19 testing will support economic recovery and a return to pre-pandemic life.

 

Current PCR-based testing efforts are crippled by constraints of an unstable supply chain of instruments, consumables and reagents, and by PCR testing systems that can process only a few thousand tests per day.

 

LGC, Biosearch Technologies offers SARS-CoV-2 testing technology that is redefining high-throughput to 35,000 patient tests per day on a single system. The FDA granted emergency use authorization (EUA) for this system.

 

We also offer an ultra-high-throughput PCR testing system is capable of processing up to 150,000 tests per day on a single system. This system is not currently granted an FDA EUA.

 

Ready to rapidly expand testing capacity with minimal need for additional staff or lab space? Learn more about our fully automated PCR systems by selecting the throughput you’d like to process on a single system.

Scale up for mass testing with ultra-high-throughput PCR capabilities. Run up to 150,000 patient samples per day per system.

 

The scientific community continues to call for large scale and frequent testing as a key response to help manage the spread of COVID-19. It will allow us to assess positivity rates in communities, measure trends and identify hot spots where additional action is required. Click below to view our mass testing infographic.

View our mass testing infographic
Highly scalable, fully automated high-throughput PCR

Biosearch Technologies’ COVID-19 PCR-based testing solutions are scalable to your desired throughput, ranging from 4,500 to 150,000 samples per day. Our high-throughput and ultra-high-throughput technologies have been used in genomics labs worldwide for over 10 years. Curious about how we’re redefining throughput for PCR-based viral detection?

 

Uniquely positioned to support mass testing

LGC’s market-leading expertise, high-quality molecular diagnostic components, and strong partner relationships has enabled the company to respond quickly to the COVID-19 pandemic since January 2020. With a history defending against public health crises such as the 2009 H1N1 Swine Flu outbreak, we are committed to being part of the worldwide solution for managing the spread of COVID-19 and beyond. Biosearch Technologies, the portfolio for genomic analysis by LGC, will allow for large-scale screening to help unlock the potential in bringing some sense of “normalcy” back into our daily activities.

 

LGC enables rapid, large-scale implementation of laboratory diagnostics for COVID-19 by expediting availability of mission-critical extraction chemistries, oligos, PCR reagents, quality control solutions, and instrumentation that deliver SARS-CoV-2 detection kits at scale.

 

LGC is proud to have worked with customers including many of the world-leading IVD companies, clinical laboratories, governments and regulatory agencies to rapidly respond to this pandemic.

Visit our COVID-19 Resources Hub

Working with you to wield science for a safer world.